PMID- 35927916
OWN - NLM
STAT- MEDLINE
DCOM- 20221228
LR  - 20230209
IS  - 2211-7393 (Electronic)
IS  - 2211-7385 (Linking)
VI  - 10
IP  - 4
DP  - 2022 Nov 15
TI  - Nanobiotechnology-Modified Cellular and Molecular Therapy as a Novel Approach for 
      Autoimmune Diabetes Management.
PG  - 279-288
LID - 10.2174/2211738510666220802111315 [doi]
AB  - Several cellular and molecular therapies such as stem cell therapy, cell 
      replacement therapy, gene modification therapy, and tolerance induction therapy 
      have been researched to procure a permanent cure for Type 1 Diabetes. However, 
      due to the induction of undesirable side effects, their clinical utility is 
      questionable. These anti-diabetic therapies can be modified with 
      nanotechnological tools for reducing adverse effects by selectively targeting 
      genes and/or receptors involved directly or indirectly in diabetes pathogenesis, 
      such as the glucagon-like peptide 1 receptor, epidermal growth factor receptor, 
      human leukocyte antigen (HLA) gene, miRNA gene and hepatocyte growth factor (HGF) 
      gene. This paper will review the utilities of nanotechnology in stem cell 
      therapy, cell replacement therapy, beta-cell proliferation strategies, immune 
      tolerance induction strategies, and gene therapy for type 1 diabetes management.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Lawand, Priyanka Vasant
AU  - Lawand PV
AD  - Department of Pharmacology, Dr. D.Y. Patil Institute of Pharmaceutical Sciences 
      and Research, Pimpri, Pune, India.
FAU - Desai, Shivani
AU  - Desai S
AD  - Department of Pharmacy Practice, Dr. D.Y. Patil Institute of Pharmaceutical 
      Sciences and Research, Pimpri, Pune, India.
LA  - eng
PT  - Journal Article
PL  - United Arab Emirates
TA  - Pharm Nanotechnol
JT  - Pharmaceutical nanotechnology
JID - 101623431
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 1/therapy/drug therapy
MH  - Immune Tolerance
MH  - *Insulin-Secreting Cells/metabolism
OTO - NOTNLM
OT  - Nanocarriers
OT  - autoimmunity
OT  - immunotherapy
OT  - stem cell
OT  - tolerance.
OT  - type 1 diabetes
EDAT- 2022/08/06 06:00
MHDA- 2022/12/29 06:00
CRDT- 2022/08/05 01:13
PHST- 2022/02/01 00:00 [received]
PHST- 2022/04/26 00:00 [revised]
PHST- 2022/05/09 00:00 [accepted]
PHST- 2022/08/06 06:00 [pubmed]
PHST- 2022/12/29 06:00 [medline]
PHST- 2022/08/05 01:13 [entrez]
AID - PNT-EPUB-125272 [pii]
AID - 10.2174/2211738510666220802111315 [doi]
PST - ppublish
SO  - Pharm Nanotechnol. 2022 Nov 15;10(4):279-288. doi: 
      10.2174/2211738510666220802111315.